Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + R-CHOP in First-line DLBCL with P53 Mutation
NCT05280626Phase 2Not yet recruiting
- Sponsor
- Innovent Biologics
- Start
- Mar 2022
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of sintilimab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Innovent Biologics. Primary endpoint: Complete Response Rate at 1 year. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05280626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05280626.